Z-LEHD-FMK (TFA)

Z-LEHD-FMK TFA is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK TFA exhibits the neuroprotective effect in a rat model of spinal cord trauma[1][2][3].

Product Specifications

CAS Number

[524746-03-0]

UNSPSC

12352209

Target

Apoptosis; Caspase

Type

Peptides

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/z-lehd-fmk-tfa.html

Solubility

H2O

Smiles

OC(C(F)(F)F)=O.O=C(OCC1=CC=CC=C1)N[C@@H](CC(C)C)C(N[C@@H](CCC(OC)=O)C(N[C@H](C(N[C@H](C(CF)=O)CC(OC)=O)=O)CC2=CN=CN2)=O)=O

Molecular Formula

C34H44F4N6O12

Molecular Weight

804.74

References & Citations

[1]Ozoren N, et, al. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000 Nov 15; 60 (22) : 6259-65.|[2]Colak A, et, al. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine. 2005 Mar; 2 (3) : 327-34.|[3]Mocanu MM, et, al. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000 May; 130 (2) : 197-200.